Gilteritinib is an FLT3 inhibitor. It’s used for AML that comes back or doesn’t respond to treatment, especially when there are FLT3 mutations. It works by blocking FLT3 kinase, which helps slow down leukemia cell growth.
The tablets are film-coated and come in 40 mg doses. For adults, the suggested dose is 120 mg, taken by mouth, once a day. You’ll get gilteritinib in bottles with 90 tablets in them.
It focuses on FLT3, a protein that’s often too much or changed in a lot of AML cases. By keeping FLT3 in check, it can help stop leukemia cells from growing too much. Gilteritinib was made to help AML patients who didn’t get better with other treatments or who didn’t respond to the first treatment.
The film-coated tablet form allows for convenient oral administration, and the supply is provided in bottles with a quantity of 90 tablets per bottle, which may last for about one month depending on the dose and the number of days in a treatment cycle.
